In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Janux Therapeutics Inc (JANX – Research Report), with a price target of $35.00. The company’s shares closed yesterday at $11.87.
Ramakanth covers the Healthcare sector, focusing on stocks such as Janux Therapeutics Inc, Vericel, and ImmunoGen. According to TipRanks, Ramakanth has an average return of -19.5% and a 23.02% success rate on recommended stocks.
Janux Therapeutics Inc has an analyst consensus of Strong Buy, with a price target consensus of $28.00.
See the top stocks recommended by analysts >>
The company has a one-year high of $23.64 and a one-year low of $10.00. Currently, Janux Therapeutics Inc has an average volume of 154.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
Read More on JANX:
